Meta-regression links each 1% weight loss on GLP-1s to 0.37 mmHg systolic drop

The wire

1. 01The EClinicalMedicine review pooled phase 3 trials of GLP-1 receptor agonists and multi-hormone receptor modulators, finding weight loss explained 76% of between-trial variance in systolic blood pressure reduction.
2. 02Prescribers managing comorbid hypertension and obesity get a quantified expectation for blood pressure change per percent of body weight lost over a median 68 weeks of treatment.
3. 03The association is drawn from between-trial meta-regression rather than individual patient data, so it cannot establish causality or predict response in any single patient.

From the source

Weight loss and blood pressure lowering with GLP-1 receptor agonists and multi-hormone receptor modulators in overweight and obesity: a systematic review and meta-regression of phase 3 clinical trials

EClinicalMedicine · 2026 Nov · Nardone M, Kugathasan L, Daunt L et al.